Anti-Mouse CD103 Antibody (M290)
Based on 1 Customer Validation
Anti-Mouse CD103 Antibody (M290) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD103. Anti-Mouse CD103 Antibody (M290) can neutralize CD103. Anti-Mouse CD103 Antibody (M290) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as B16.gp33 tumor, colitis and diabetes.
For research use only. We do not sell to patients.
- Purity: 98.93%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2a kappa
Mouse
CD103
Anti-Mouse CD103 Antibody (M290) (M290-MC-MMAF, N290 conjugated with Maleimidocaproyl-monomethyl auristatin F) (0-10 μg/mL, 48 h) reduces and inhibits the proliferation of CD8+ T cells in splenic lymphocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse CD103 Antibody (M290) (1 mg at 1 day after T cell reconstitution and 0.5 mg twice a week for 8 weeks, i.p.) abrogates suppression of colitis by CD4+CD45RBlow T cells in colitis mice models[2].
Anti-Mouse CD103 Antibody (M290) (M290-MC-MMAF, M290 conjugated with Maleimidocaproyl-monomethyl auristatin F) (3 mg/kg, i.p., at days 1, 3 and 5) promotes pancreatic islet allograft survival in diabetic C57BL/6 mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c islet allografts were transplanted into diabetic C57BL/6 mice[3]
-
Dosage:3 mg/kg (M290-MC-MMAF, N290 conjugated with Maleimidocaproyl-monomethyl auristatin F)
-
Administration:Intraperitoneally injection, at days 1, 3 and 5
-
Result:Prolonged islet allograft survival (>60 days).
Revealed that fewer immune cells infiltrated the islet allografts.
Showed more residual islets and an insulin-positive mass in the grafts.
Prevented leukocyte infiltration and increased insulin secretion.
Eliminated the CD8+CD103+ T-cell subpopulation.
Reduced the levels of IL-4, IL-6, and TNF-α.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo CD103 neutralization; Immunofluorescence; Flow cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD103 Antibody (M290)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Liikanen I, et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021 Apr 1;131(7):e143729. [Content Brief]
[2]. Annacker O, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005 Oct 17;202(8):1051-61. [Content Brief]
[3]. Xue D, et al. An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice. Cell Death Dis. 2019 Sep 30;10(10):735. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD103 Antibody (M290) Related Classifications
HY-P990295 Related Classifications
Powered by Bioz